Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) have earned a consensus recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $38.60.
Several equities analysts have recently weighed in on the company. Needham & Company LLC lifted their price objective on Nurix Therapeutics from $35.00 to $44.00 and gave the company a “buy” rating in a report on Friday. Zacks Investment Research upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 15th. Finally, Robert W. Baird assumed coverage on Nurix Therapeutics in a research note on Wednesday, November 18th. They issued an “outperform” rating and a $40.00 target price on the stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NRIX. Wells Fargo & Company MN bought a new stake in Nurix Therapeutics in the 3rd quarter valued at approximately $1,230,000. California Public Employees Retirement System bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth approximately $879,000. New York State Common Retirement Fund bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth approximately $221,000. TRV GP Iii LLC bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth approximately $189,301,000. Finally, BlackRock Inc. bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth approximately $23,383,000. Hedge funds and other institutional investors own 34.36% of the company’s stock.
NASDAQ:NRIX opened at $40.24 on Thursday. Nurix Therapeutics has a fifty-two week low of $15.21 and a fifty-two week high of $52.38. The company’s 50-day simple moving average is $39.28.
Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Monday, October 19th. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.18). The firm had revenue of $4.09 million during the quarter, compared to analyst estimates of $7.35 million. On average, analysts forecast that Nurix Therapeutics will post -1.97 earnings per share for the current fiscal year.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications.
Further Reading: Trading Strategy Examples and Plans